Patients come from populations and populations contain patients. A two-stage scientific and ethics review: The next adaptation for single institutional review boards

David S Knopman, Eli Alford, Kaitlin Tate, Mark Long, Ara S. Khachaturian

Research output: Contribution to journalShort surveypeer-review

10 Scopus citations

Abstract

Introduction For nearly 50 years, institutional review boards (IRB) and independent ethics committees have featured local oversight as a core function of research ethics reviews. However growing complexity in Alzheimer's clinical research suggests current approaches to research volunteer safety is hampering development of new therapeutics. As a partial response to this challenge, the NIH has mandated that all NIH-funded multi-site studies will use a single Institutional Review Board. The perspective describes a joint program to provide a single IRB of record (sIRB) for phases of multi-site studies. Methods The approach follows two steps. One, an expert Scientific Review Committee (SRC) of senior researchers in the field will conduct the review principally of scientific merit, significance, feasibility, and the likelihood of meaningful results. The second step will be the IRB's regulatory and ethics review. The IRB will apply appropriate regulatory criteria for approval including minimization of risks to subjects and risks reasonable in relation to anticipated benefits, equitable subject selection, informed consent, protections for vulnerable populations, and application of local context considerations, among others. Results There is a steady demand for scientific, ethical and regulatory review of planned Alzheimer's studies. As of January 15, 2017, there are nearly 400 open studies, Phase II and III, industry and NIH sponsored trials on disease indications affecting memory, movement and mood in the US. Conclusions The effort will initially accept protocols for studies of Alzheimer's disease, dementia, and related disorders effecting memory, movement and mood. Future aims will be to provide scientific review and, where applicable, regulatory and ethical review in an international context outside North America with sites possibly in Asia, Europe and Australia.

Original languageEnglish (US)
Pages (from-to)940-946
Number of pages7
JournalAlzheimer's and Dementia
Volume13
Issue number8
DOIs
StatePublished - Aug 1 2017

Keywords

  • Alzheimer's
  • Clinical trial
  • Dementia
  • EMEA
  • Ethics
  • FDA
  • Intervention
  • IRB
  • Prevention
  • Therapeutic
  • Treatment

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Geriatrics and Gerontology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Patients come from populations and populations contain patients. A two-stage scientific and ethics review: The next adaptation for single institutional review boards'. Together they form a unique fingerprint.

Cite this